AML Course 3 – Optimising outcomes in AML: The role of HCT

Charles Craddock

University of Birmingham, Birmingham, United Kingdom

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci, is Professor of Hemato-oncology at the University of Birmingham, Birmingham, UK, and Academic Director of the Centre for Clinical Haematology at the Queen Elizabeth Hospital, Birmingham, UK.

Prof. Craddock qualified at the University of Oxford, Oxford, UK, first obtaining his undergraduate degree in Physiological Sciences in 1979, before completing his MBBCh and his DPhil in 1982 and 1994 respectively. He became a fellow of both the Royal College of Physicians and the Royal College of Pathologists in 2008. Prof. Craddock trained in hematology at the Hammersmith Hospital in London, UK, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, WA.

As Director of the BMT Unit at the Queen Elizabeth hospital in Birmingham, Prof. Craddock drove the establishment and subsequent expansion of the £7 million Centre for Clinical Haematology at the Queen Elizabeth Hospital and, as Director of Birmingham Health Partners, led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015.

Prof. Craddock is Chair of the NCRI Acute Myeloid Leukaemia Working Group and leads the UK Haemato-oncology Trials Acceleration Programme, as well as being elected President of the British Society of Haematology in 2017. He was awarded the CBE for services to medicine and medical research in the 2016 New Year’s Honours list.

Naval Daver

The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Dr Naval Daver is an associate professor and director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease, and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials in these diseases, including multiple registration and label enabling trials.

These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr Daver has published more than 400 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals. He also serves as Chair on numerous national and international meetings and educational platforms.